Filtros de búsqueda

Lista de obras de

#523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)

A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

artículo científico publicado en 2016

A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecolog

scientific article published on 31 August 2018

A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor–Positive Advanced or Recurrent Endometrial Cancer

artículo científico publicado en 2024

A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer

scientific article published on 01 July 2018

A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer

artículo científico publicado en 2014

A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study).

artículo científico

A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome

artículo científico publicado en 2017

A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer

scientific article published on 17 January 2020

A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.

artículo científico publicado en 2016

A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers

artículo científico publicado en 2020

A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer

scientific article published on 07 November 2019

A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors

artículo científico publicado en 2007

A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer

artículo científico publicado en 2008

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies

artículo científico publicado en 2002

A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors

artículo científico publicado en 2018

A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study

artículo científico publicado en 2009

A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study

artículo científico

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study

article

A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission.

artículo científico publicado en 2007

A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study

artículo científico publicado en 2016

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An

artículo científico publicado en 2015

A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission:

scientific article published on 22 October 2019

A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer

article

A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer

artículo científico publicado en 2018

A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study

scientific article published on 23 December 2018

A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma

artículo científico publicado en 2008

A systematic review of ovarian cancer and fear of recurrence

artículo científico publicado en 2015

Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models

scientific article published on 11 December 2019

Adjuvant chemotherapy in patients with operable granulosa cell tumors of the ovary: a surveillance, epidemiology, and end results cohort study.

artículo científico publicado en 2018

Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study

artículo científico publicado en 2009

Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group

artículo científico publicado en 2004

Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy

artículo científico publicado en 2002

Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer

artículo científico publicado en 2019

Association of ß-hCG Surveillance with Emotional, Reproductive, and Sexual Health in Women Treated for Gestational Trophoblastic Neoplasia

artículo científico publicado en 2017

Authors' reply to Drs. Khattak and Martin

BRAF Mutation is associated with early stage disease and improved outcome in patients with low‐grade serous ovarian cancer ⬇️

artículo científico publicado el 28 de agosto de 2012

BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer

scientific article published on 16 June 2020

Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study

artículo científico publicado en 2020

Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer

artículo científico publicado en 2014

Brain metastasis in advanced serous borderline tumor of the ovary: A case presentation

artículo científico publicado en 2017

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy

artículo científico publicado en 2006

Cancer-related infertility in survivorship

artículo científico publicado en 2010

Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery

artículo científico publicado en 2020

Chemotherapy response in low‐grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies

artículo científico publicado en 2023

Chemotherapy-induced dyspareunia: a case study of vaginal mucositis and pegylated liposomal doxorubicin injection in advanced stage ovarian carcinoma

artículo científico publicado en 2004

Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology

artículo científico publicado en 2013

Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer

artículo científico publicado en 2018

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status

article

Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology

artículo científico publicado en 2011

Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology

artículo científico publicado en 2012

Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer

scientific article published on 19 November 2019

Clinical update: novel targets in gynecologic malignancies

artículo científico publicado en 2004

Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer.

artículo científico publicado en 2008

Consolidation strategies in ovarian cancer: observations for future clinical trials

artículo científico publicado en 2010

Corrigendum to "Brain metastasis in advanced serous borderline tumor of the ovary: A case presentation" [Gynecol. Oncol. Rep. 22 (2017) 9-12].

artículo científico publicado en 2017

Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer

artículo científico publicado en 2004

Craniotomy for central nervous system metastases in epithelial ovarian carcinoma

artículo científico publicado en 2002

Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009

artículo científico publicado en 2010

Data from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Data from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Data from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer

artículo científico publicado en 2020

Development of a risk stratification system to guide treatment for female germ cell tumors.

artículo científico publicado en 2015

Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients

scientific article published on 19 June 2019

Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer

artículo científico publicado en 2017

Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials

scientific article published on 05 July 2007

Early detection and prognosis of ovarian cancer using serum YKL-40.

artículo científico publicado en 2004

Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade

scientific article published on 22 November 2018

Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

artículo científico publicado en 2015

Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial

artículo científico publicado en 2020

En bloc resection of diaphragm with lung for recurrent ovarian cancer: a case report

scientific article published on 19 June 2006

Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study

artículo científico publicado en 2011

Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study

artículo científico publicado en 2020

Extrauterine epithelioid trophoblastic tumors presenting as primary lung carcinomas: morphologic and immunohistochemical features to resolve a diagnostic dilemma

artículo científico publicado en 2009

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer

artículo científico publicado en 2015

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer

scientific article published on 19 June 2019

Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.

artículo científico publicado en 2015

Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I–II papillary serous endometrial cancer ⬇️

artículo científico publicado el 28 de julio de 2012

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

artículo científico publicado en 2002

Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience

artículo científico publicado en 2012

Genomic complexity and AKT dependence in serous ovarian cancer

artículo científico publicado en 2012

Germline Pathogenic Variants and Genetic Counseling by Ancestry in Patients With Epithelial Ovarian Cancer

artículo científico publicado en 2023

Germline drivers of gynecologic carcinosarcoma (2274)

artículo científico publicado en 2023

Germline drivers of gynecologic carcinosarcomas

artículo científico publicado en 2023

Germline variants in non-BRCA1/2 homologous recombination-related genes and ovarian cancer: Analysis of tumor phenotype and survival.

artículo científico publicado en 2023

Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma

scientific article published on 01 May 2006

Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era.

artículo científico publicado en 2013

Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.

artículo científico publicado en 2017

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

artículo científico publicado en 2015

Identifying Clinical Improvement in Consolidation Single-Arm Phase 2 Trials in Patients With Ovarian Cancer in Second or Greater Clinical Remission ⬇️

artículo científico publicado el 1 de enero de 2012

Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma

artículo científico publicado en 2011

Impact of Provider Imaging Practices on Survival Outcomes in Advanced Ovarian Cancer

scientific article published on 01 April 2020

Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer

artículo científico publicado en 2020

Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm

scientific article published on 23 April 2009

Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer

artículo científico publicado en 2011

Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma

article

Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies

artículo científico publicado en 2009

Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma

scientific article published on 01 April 2020

Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer

artículo científico

Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: A Gynecologic Oncology Group Study ⬇️

artículo científico publicado el 24 de mayo de 2012

Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy

artículo científico publicado en 2016

Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up

scientific article published on 01 February 2002

Intraperitoneal chemotherapy in older women with epithelial ovarian cancer

article

Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial

artículo científico publicado en 2004

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

artículo científico publicado en 2020

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

artículo científico publicado en 2019

Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival

scientific article published on 01 October 2006

MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma

artículo científico publicado en 2022

MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

artículo científico publicado en 2020

Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers

artículo científico publicado en 2020

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

article

Management and outcome of healthy women with a persistently elevated beta-hCG.

artículo científico publicado en 2007

Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation

artículo científico publicado en 2022

Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses

artículo científico publicado en 2018

Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes (1242)

artículo científico publicado en 2023

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

artículo científico publicado en 2023

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) ⬇️

artículo científico publicado en 2021

Molecular profiling and molecular classification of endometrioid ovarian carcinomas

artículo científico publicado en 2019

Mutant FOXL2C134W highjacks SMAD4 and SMAD2/3 to drive adult granulosa cell tumors

artículo científico publicado en 2020

Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center

artículo científico publicado en 2016

Niraparib in Recurrent Ovarian Cancer

artículo científico publicado en 2017

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer ⬇️

artículo científico publicado el 23 de abril de 2012

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial

scientific article published on 14 March 2019

Ovarian cancer mutational processes drive site-specific immune evasion

artículo científico publicado en 2022

Ovarian clear cell carcinoma, outcomes by stage: the MSK experience

artículo científico publicado en 2015

PO004LBA/#1515 Efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy

Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial

artículo científico publicado en 2017

Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study

artículo científico publicado en 2006

Palliative surgery for bowel obstruction in recurrent ovarian cancer:an updated series ⬇️

artículo científico publicado el 1 de mayo de 2003

Paraneoplastic opsoclonus-myoclonus syndrome secondary to immature ovarian teratoma

artículo científico publicado en 2010

Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival

artículo científico publicado en 2024

Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma

artículo científico publicado en 2020

Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors

artículo científico publicado en 2010

Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors

artículo científico publicado en 2009

Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway

artículo científico publicado en 2019

Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors

artículo científico publicado en 2004

Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma

artículo científico publicado en 2011

Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

artículo científico publicado en 2006

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas

artículo científico publicado en 2007

Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning

artículo científico publicado en 2006

Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study ⬇️

artículo científico publicado el 2 de mayo de 2011

Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study

scientific article published on 03 July 2018

Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N

artículo científico publicado en 2015

Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

artículo científico publicado en 2004

Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer

scientific article published on 01 October 2020

Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study

artículo científico publicado en 2020

Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer

artículo científico publicado en 2011

Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study

artículo científico publicado en 2012

Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash

artículo científico publicado en 2009

Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer

artículo científico publicado en 2019

Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer

scientific article published on 17 April 2019

Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.

artículo científico publicado en 2018

Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer

artículo científico publicado en 2007

Placental site trophoblastic tumor: Analysis of presentation, treatment, and outcome ⬇️

artículo científico publicado el 26 de diciembre de 2012

Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy ⬇️

artículo científico publicado el 1 de octubre de 2003

Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study

artículo científico publicado en 2020

Predicting outcomes in female germ cell patients using a modified International Germ Cell Cancer Collaborative Group classification system to guide management (100)

artículo científico publicado en 2022

Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management

artículo científico publicado en 2023

Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer

article

Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up

artículo científico publicado en 2008

Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer

article

Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residu

artículo científico publicado en 2007

Radiation therapy for epithelial ovarian cancer brain metastases: clinical outcomes and predictors of survival ⬇️

artículo científico publicado el 15 de febrero de 2013

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

artículo científico publicado en 2016

Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

artículo científico publicado en 2020

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

scientific article published on 19 April 2019

Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study

artículo científico publicado en 2018

Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study

artículo científico publicado en 2017

Response and outcomes in elderly patients with stages IIIC–IV ovarian cancer receiving platinum–taxane chemotherapy

artículo científico publicado en 2007

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

artículo científico publicado en 2020

Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience

Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer

artículo científico publicado en 2002

Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes

artículo científico publicado en 2021

Role of pegylated liposomal doxorubicin in ovarian cancer

artículo científico publicado en 2005

Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial

scientific article published on 01 May 2020

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

artículo científico publicado en 2017

Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.

artículo científico publicado en 2008

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study

artículo científico publicado en 2019

Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

artículo científico publicado en 2020

Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer

scientific article published on 27 November 2019

Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature

artículo científico publicado en 2007

Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer

artículo científico publicado en 2019

Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Surgical resection of recurrent endometrial carcinoma

artículo científico publicado en 2006

Temozolomide in uterine leiomyosarcomas

artículo científico publicado en 2005

The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer

article

The benefit of video-assisted thoracoscopic surgery before planned abdominal exploration in patients with suspected advanced ovarian cancer and moderate to large pleural effusions

artículo científico publicado en 2004

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

scientific article published on 31 July 2020

The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer

artículo científico publicado en 2007

The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center

artículo científico publicado en 2006

The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment

artículo científico publicado en 2009

The role of bevacizumab in ovarian cancer--an evolving story

scientific article published on 01 August 2006

The role of systemic chemotherapy in the management of granulosa cell tumors

artículo científico publicado en 2014

Therapeutic Implications of Germline Testing in Patients With Advanced Cancers

artículo científico publicado en 2021

Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma

artículo científico publicado en 2004

Transforming ovarian cancer care by targeting minimal residual disease

artículo científico publicado en 2023

Treatment of Low-Risk Gestational Trophoblastic Neoplasia ⬇️

artículo científico publicado el 24 de enero de 2011

Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.

artículo científico publicado en 2013

Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors

artículo científico publicado en 2009

Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience

artículo científico publicado en 2003

Treatment outcomes in completely resected stage I to stage IV uterine carcinosarcoma with rhabdomyosarcoma differentiation

artículo científico publicado en 2013

Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer

artículo científico publicado en 2016

Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer

artículo científico publicado en 2019

Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series

artículo científico publicado en 2007

Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations

artículo científico publicado en 2016

Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy

artículo científico publicado en 2020

Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation

artículo científico publicado en 2022

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

artículo científico publicado en 2019

Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature

artículo científico publicado en 2004

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda